Adhesive glycoproteins in the bone matrix are of critical importance for cell anchorage, proliferation, migration, differentiation, and regulation of bone metabolism. The localization of the adhesive glycoprotein vitronectin (Vn) in murine bone tissue was evaluated by immunohistochemical staining. Vitronectin was present throughout the mineralized bone matrix of cancellous and cortical bone, whereas cartilage was devoid of Vn staining. To exclude the possibility that the positive Vn staining resulted from plasma Vn in blood vessels within the bone sections, adjacent tissue sections were stained with antibodies to fibrinogen, an abundant plasma protein. Fibrinogen immunoreactivity was confined to blood vessels in the bone marrow and Haversian system, whereas the mineralized bone matrix was devoid of staining. The presence of Vn in murine bones was confirmed by sequential extraction, followed by fractionation of the resulting polypeptides by gel electrophoresis and immunoblotting analysis. Hydroxyapatite affinity chromatography raises the possibility that m i n d interactions, at least in part, mediate the incorporation of Vn into the bone matrix. These results indicate that Vn is a specific component of bone tissue and raise the possibility that Vn is involved in regulation of bone metabolism. (JHistochem Cyrocbem 4:275-280,   1%) 
Introduction
Vitronectin (Vn) not only belongs to a group of adhesion molecules that mediate cell attachment through a common Arg-Gly-Asp-dependent mechanism but also appears to regulate the complement, coagulation, and fibrinolytic systems (reviewed in 1J). Regulation of these proteolytic enzyme cascades is critically important during hemostasis, wound repair, neoplasia, inflammation, tissue remodeling, and morphogenesis (3,4). Therefore, Vn may provide a unique regulatory link between cell adhesion, humoral defense mechanism, and cell invasion (1) .
Compelling experimental evidence has accumulated during the last few years suggesting that adhesive events are of critical importance for bone functions (5-8). For example, the initial adhesive interaction of the osteoclast with adhesive glycoproteins on the bone surface is absolutely required to initiate bone resorption. Specific cell surface receptors are expressed on a number of cells, including osteoclasts, and are collectively termed integrins (9.10). These receptots mediate the adhesive interaction of cells with adhesive glycoproteins in the extracellular matrix. Each integrin is a noncovalently associated ap heterodimer that spans the plasma membrane. The major Vn receptor appears to be a&, which is expressed on mature osteoclasts, and this receptor clearly regulates bone resorption (1, 2, 11) The present study provides evidence that Vn is a specific component of the mineralized bone matrix. This conclusion is based on sequential dissociative extraction of bone tissue, hydroxyapatite affinity chromatography, and immunohistochemical localization of Vn in the mineralized bone matrix. These observations raise the possibility that Vn is a physiological ligand for the integrin a43 in bone tissue.
Materials and Methods
Tissue Preparation. All animal experiments were performed in accordance with the Scripps Research Institute's guide for care and use of laboratory animals. Balblc x C57BllF1 mice (6-8 weeks old; Scripps Clinic Rodent Breeding Colony) were sacrificed by overdose inhalation anesthesia with Metofane (methoxyflurane; Pitman-Moore, Mundelelein, IL). Selected skeletal tissues were removed surgically and immersed in chilled 4% paraformaldehyde in 50 mM phosphate buffer, pH 7.4. The tissues were fixed overnight, decalcified for 2 hr at room temperature (RT) with 10% nitric acid, neutralized by extensive washing in 50 mM phosphate buffer, pH 7.4, and embedded in paraffin blocks. Tissues were sectioned at 3-pm thickness, mounted on slides (Fisher Superfrost Plus; Fisher Scientific, Pittsburgh, PA), and stored at RT for up to 48 hr pending analysis. For some experiments, isolated femurs were quick-frozen in liquid nitrogen, homogenized in the frozen state, and extracted as described (12). Briefly, homogenized bone was first extracted with 4 M guanidine HCI (GnHCI) containing 5 mM benzamidine HCI and 1 mM phenylmethylsufonyl fluoride for 3 days at 4'C by end-over-end rocking. The samples were centrifuged at 3000 x g for 20 min at 4°C and the insoluble material was subsequently extracted for 3 days with the above buffer now containing 500 mM EDTA. Again, the samples were spun to separate insoluble materials. The insoluble material was resuspended in 10 mM Tris-HCI, pH 7.4, containing 8 M urea. Finally, the GnHCl and GnHCI-EDTA extraction fractions were dialyzed against PBS. The dialyzed fractions were centrifuged at 3000 x g for 20 min at 4°C and the insoluble pellet was redissolved in 10 mM Tris-HCI. pH 7.4, containing 8 M urea.
Antibodies. Antibodies to purified murine Vn were raised in rabbits as described previously (13). The Vn preparation used for the immunization was homogeneous as judged by SDS-PAGE, followed by staining with silver nitrate, and by N-terminal sequence analysis (13). IgG was purified from the crude antiserum by protein A affinity chromatography as described (14) . For some experiments the purified IgG fraction was immunoabsorbed by Vn affinity chromatography. Briefly, purified murine Vn was coupled to CNBr-activated Sepharose CL-4B beads (Pharmacia; Uppsala, Sweden) at 250 pglml settled beads according to the instructions of the manufacturer. The IgG fraction was circulated over the column for 16 hr at 4°C. The integrity of the nonbound IgG was evaluated by SDS-PAGE, followed by staining with silver nitrate (not shown). This procedure resulted in an approximately 1000-fold reduction of specific IgG as revealed by solid-phase binding assays to immobilized murine Vn (not shown). Antibodies to murine fibrinogen were kindly provided by Dr. E. Plow (Cleveland Clinic Foundation; Cleveland, OH).
Immunohistochemistry. Immunohistochemical staining was performed using the Histostain-SP kit (Zymed Laboratories; South San Francisco, CA) as described (15) . Briefly, paraffin-embedded, paraformaldehyde-fixed sections were deparaffinized, endogenous peroxidase activity was quenched with hydrogen peroxide, and finally tissues were rehydrated and permeabilized. The sections were incubated with 0.23% pepsin at 37°C for 5 min to unmask antigens. This procedure increased the immunohistochemical staining intensity, but a strong and specific signal was already detectable without unmasking. The sections were rinsed and blocked with 10% normal goat serum in PBS. The tissue sections were incubated with rabbit antimurine Vn IgG (10 pglml) or rabbit antimurine fibrinogen (1:SOOO dilution of crude antiserum) in PBS containing 0.1% (v/v) normal goat serum in a humidified chamber overnight at 4'C. followed by an incubation of 1 hr at 2S'C. After washing, the biotinylated secondary antibody (Zymed; 1:lOO diluted in PBS containing 0.05% Tween-20) was added and allowed to react for 20 min. The tissue sections were washed, incubated with streptavidin-peroxidase conjugate (Zymed; 1 100 diluted in PBS), washed, and then developed with freshly prepared am noethylcarbazole chromogen containing 0.03% hydrogen peroxide for up to 10 min. After rinsing in distilled water, the sections were counterstained with Gill's hematoxylin for 30 sec, rinsed in water, dried, and mounted in Aquamount (Lerner; Pittsburgh, PA). To evaluate the specificity of the immunostaining, the following controls were included on adjacent tissue sections on the same slide:
(a) nonimmune rabbit IgG (at the same IgG concentration as the antibody; Sigma Diagnostics, St Louis, MO); (b) immunoabsorbed antimurine Vn IgG (see above) at the same IgG concentration; and (c) omission of the primary antibodies.
Binding of Vn to Hydroxyapatite Crystals. The binding of Vn to minerals in bone was tested by hydroxyapatite affinity chromatography. Vn was purified from human serum according to Yatogho et al. (16) and 1 mg was applied to 5 ml hydroxyapatite crystals (Calbiochem; La Jolla, CA) equilibrated in 10 mM Tris-HCI, pH 7.4, containing 140 mM NaCI. The crystals were washed with 10 column volumes of equilibration buffer and developed with a linear gradient of phosphate buffer, pH 7.0 (0-1 M; 100 ml in each vessel) at a flow rate of 66 ml/hr and 5.5-ml fractions were collected. Then the column was stepwise eluted with 20 ml each of 0.6. 0.7, 0.8, 0.9, and 1.0 M phosphate buffer, pH 7.0. Finally, the hydroxyapatite minerals were boiled in 1% SDS. The Vn concentrations in the starting material, nonbound fraction, wash, and elution fractions were quantified by a sandwich ELISA. Briefly, microtiter wells were coated with antihuman Vn IgG (clone 17.26) and incubated with Vn-containing samples. Bound Vn was detected with rabbit antihuman Vn IgG. followed by biotin-labeled goat antirabbit IgG, streptavidin-alkaline phosphatase complex, and pNPP. The change of absorbance was linear for Vn concentrations of 1-400 ng/ml. A standard curve was constructed using serial dilutions of the starting material.
Miscellaneous. SDS-PAGE was performed in slab gels according to Laemmli (17) . The upper stacking gel contained 4% acrylamide and the lower resolving gel contained 9% acrylamide. Reduction of samples was carried out by addition of dithiothreitol (50 mM) to the sample buffer. Immunoblotting analysis of bone extracts separated by SDS-PAGE and transferred to nitrocellulose was performed essentially as described using rabbit antimurine Vn (1:500 dilution of the antiserum) or rabbit antimouse fibrinogen (1:500 dilution of the antiserum), respectively (14) .
Results
The localization of Vn in bone tissue was evaluated by immunohistochemical staining. Strong lamellar staining for Vn was present with variable intensity throughout the cortical bone tissue of the femur diaphysis (Figure 1A , upper half). Evaluation of the femur corticalis at higher magnification revealed that the positive Vn staining was associated with the mineralized bone matrix and also with blood vessels within the Haversian canals ( Figure 1B ). The strongest Vn staining was observed in the matrix around but not immediately adjacent to blood vessels (Figure 1B) . In general, bone cells (i.e., osteocytes) in the femur diaphysis were negative or were stained only weakly for Vn ( Figure 1B) . The bone marrow cavity was almost devoid of Vn signal ( Figure 1A , lower half). No specific staining was observed when the antibodies were immunoabsorbed ( Figure IC) . The Vn staining was not restricted to compact bone in the femur. Immunohistochemical evaluation of the ankle joint revealed that trabecular bones of the tibia and talus epiphysis were also strongly positive for Vn ( Figure ID) . In contrast, the articular cartilage was devoid of Vn staining ( Figure ID ). In addition, Vn was also detected in the mineralized matrix of cortical bone and in some osteocytes in vertebrae ( Figure 1E ). Immunohistochemical analysis of cross-sections through cartilaginous ribs revealed that Vn was absent from nonmineralized skeletal tissues ( Figure IF) , whereas capillaries in the surrounding skeletal muscle contained Vn antigen ( Figure IF) . The absence of Vn in cartilage was confirmed in a high-power view of the hyaline cartilage of murine ribs ( Figure 1G ).
Not only is bone a highly vascularized organ, but Vn also constitutes up to 0.5% of total plasma proteins (reviewed in 2). To exclude the possibility that the positive Vn staining resulted from residual plasma Vn in blood vessels within the bone sections, adjacent sections were stained with antibodies to murine fibrinogen, a marker for plasma proteins (Figures 1H and 11 ). Although the bone marrow (Figure lH , lower half) and the highly vascularized periosteum (not shown) stained strongly for fibrinogen, no specific staining was detected in the cortical bone tissue at low-power view (Figure lH, upper half) . A high-power view of the cortical bone of the femur revealed that fibrinogen immunoreactivity was present within blood vessels of the Haversian canals but was absent from the bone matrix and bone cells ( Figure 11 ).
A sequential dissociative extraction scheme was employed to confirm the presence of Vn in bone tissue and to obtain some initial information regarding the nature of the molecule(s) that might mediate the incorporation into the bone matrix ( Figure 2 ). Bone tissue was homogenized and extracted with GnHCI, followed by extraction with GnHCI-EDTA. The resulting polypeptides were analyzed by SDS-PAGE, followed by staining with silver nitrate (Figure 2A ). The electrophoretic mobility of the extracted proteins was compared to that of purified murine Vn (Figure 2A , Lane 1) and murine plasma (Figure 2A, Lane 2) . The protein profiles in each extraction fraction (Figure 2A , Lanes 3-7) are distinct from that of plasma, indicating that this procedure resulted in a substantial enrichment of bone-derived proteins (Figure 2A ). Immunoblotting analysis using antibodies to murine Vn revealed that significant amounts of Vn-related polypeptides of reported MI 71,000 (13) and approximately 62,000 were present in the GnHCIIEDTA bone extracts ( Figure 2B) . The Mr 71,000 Vn-related polypeptide comigrated with Vn in plasma and purified Vn (compare Figure 2B , Lanes 1, 2, and 5). In addition, higher molecular weight Vn aggregates were present in the extraction fractions ( Figure 2B , Lanes 5 and 6). The majority of Vn was released from the bone tissue after extraction with GnHCI-EDTA in the PBS-soluble and GnHCI-EDTA PBS-insoluble fractions (Figure 2B , Lanes 5 and 6), but significant amounts of Vn were also detected in the insoluble fraction ( Figure ZB, Lane 7) . In contrast, GnHCl extraction alone was not sufficient to release significant amounts of Vn from the bone tissue. No crossreactivity of the antibodies with other proteins in the bone extract or plasma was detectable on fractionation on a 9% SDS gel ( Figure 2B ) or a 15% SDS gel (not shown). The extent of cross-contamination of the extraction fractions with plasma proteins was evaluated by immunoblotting using antibodies to fibrinogen. Although fibrinogen was easily detectable in murine plasma (Figure 2A, Lane 1) . it was undetectable in any of the extraction fractions, as exemplified for the GnHCI-EmA PBS-soluble fraction in Figure 2C , Lane 2. Therefore, the differential extraction experiments revealed that Vn is present in and is strongly bound to bone tissue. The requirement of EDTA for extraction raises the possibility of an interaction of Vn with minerals in the bone matrix (12).
To further understand the nature of macromolecules involved in the incorporation of Vn into bone tissue, binding of Vn to minerals was tested by hydroxyapatite affinity chromatography (Table l). Vn bound quantitatively to hydroxyapatite crystals and was eluted as a minor peak between 50 and 130 mM phosphate buffer, with a peak elution at 70 mM, whereas the majority of the Vn (85Oh) remained bound in phosphate concentrations up to 1 M and was released only by boiling in SDS. These results indicate that Vn has a high affinity for hydroxyapatite and raise the possibility that mineral interactions, at least in part, mediate binding of Vn to the bone matrix.
Discussion
The results of this study demonstrate that Vn is a specific component of bone tissue. This conclusion is based on immunohistochemical in situ localization studies (Figure 1) and on the extraction of Vn polypeptides from murine long bones (Figure 2) . A number of experiments were performed to exclude the possibility that the antibodies used in these experiments crossreact with other proteins in bone. These included the absence of staining of adjacent tissue sections processed on the same slide when preimmune rabbit IgG was employed (not shown) or when the specific IgG was absorbed on murine Vn Sepharose-4B ( Figure IC ). In addition, the antibodies failed to interact with immobilized osteopontin, excluding the possibility that the antibodies detect the RGD sequences present in a number of bone matrix proteins (not shown).
Vitronectin purified in the presence of protein denaturants or extracted under denaturing conditions (e.g., GnHCI) forms high molecular weight aggregates that are only partially reversed by SDS-PAGE and mild reducing conditions (1.2). Therefore, the purified Vn standard and the extracted polypeptides contain both monomeric murine Vn (MI 71,000) and higher molecular weight aggregates that should not be viewed as crossreacting proteins. It should be noted that the extraction fractions also contained smaller Vn polypeptides of approximately MI 62,000 ( Figure 2B ). It is presently unknown whether this lower molecular weight Vn species is derived from proteolytic cleavage during the extraction procedure or from a different processing of Vn in bone tissues. In this respect it should be noted that the presence of Vn could also be demonstrated when bone was differentially extracted for 15 min with a nonionic detergent (1./0 Triton X-loo), followed by a 1-hr extraction with an ionic detergent (10% SDS). Although this extraction procedure did not result in complete dissolution of the bone tissue, the majority of the Vn was present as a single M, 71,000 polypeptide in the SDS fraction (not shown). This result raises the possibility that the M r 62.000 polypeptide was derived from proteolytic degradation during the prolonged (i.e., 6-day) extraction with GnHCl and/or GnHCI-EDTA. The origin of Vn in the bone matrix is presently unknown. Although the liver was initially identified as the major source of Vn biosynthesis in vivo (13). recent studies indicate that extrahepatic tissues also express the Vn transcript (18) . Polymerase chain reactionbased experiments revealed that Vn mRNA is present in total RNA extracted from murine femurs (data not shown). However, because the Vn message level was below the detection limit of our in situ hybridization procedure (data not shown), a positive cell type could not be identified. As a positive control for the integrity of the RNA in the fixed tissue, adjacent sections were hybridized with an antisense probe for GAPDH and the success of the Vn hybridization was tested using murine liver sections as an abundant source of Vn mRNA. Therefore, the amplified Vn transcript might be derived from low-level expression of actual bone cells, from cells present in the bone marrow, or from other tissues within the bone. High levels of Vn expression during earlier developmental stages appear to be unlikely to account for the presence of Vn in the bone matrix, because we were unable to detect Vn mRNA in embryonic bone tissues between Days 10 and 18 of gestation (19) .
The high affinity of hydroxyapatite for many proteins presumably allows absorption from blood, which results in a concentration of a number of circulating proteins in bone (20). Alternatively, a number of cells express integrin-dependent andlor glycosaminoglycan-dependent binding sites for Vn (21,22) , and Vn is transcytosed by cells into the extracellular matrix (23-25). Similar mechanisms could also account for the presence of Vn in the bone matrix. Therefore, the origin of Vn present in bone remains to be elucidated.
The extraction experiments suggest that Vn is strongly associated with the bone tissue. GnHCl extraction alone was not sufficient to release Vn from bone, whereas a combined extraction with GnHCl and EDTA was required to solubilize Vn polypeptides (Figure 2) . The latter step dissolves the mineralized portion of the tissue and extracts noncollagenous proteins closely associated with hydroxyapa- rite crystallites in the mineralized matrix (12). This result raises the possibility that Vn is associated with apatite in the bone matrix. This concept is supported by the high affinity of Vn for hydroxyapatite minerals in vitro (Table 1) . It should be noted that the phosphate concentration required for the elution is a direct reflection of the relative affinity of a macromolecule for apatite (26). However, both the extraction experiments and the hydroxyapatite affinity chromatography should not be viewed as proof that apatite alone is sufficient or the only possible mechanism to account for the binding of Vn to the mineralized bone matrix. In this respect it should be noted that Vn interacts with a number ofother macromolecules (reviewed in 27) that are expected to be found in the bone matrix, including collagen (28). and glycosaminoglycans (reviewed in 2). raising the possibility that Vn may be part of a macromolecular complex in the bone matrix.
The function(s) of Vn in bone is presently unknown. One intriguing possibility is that Vn regulates bone remodeling. This process is brought about by the coordinate but opposing actions of osteoclasts and osteoblasts (20.29). The adhesion of osteoclasts to bone is an ongoing dynamic process involving several steps of cell adhesion and release. Blockage of this adhesion event will effectively slow or eliminate bone resorption (8). The major Vn appears to be a&, which is expressed on the surface of mature osteoclasts, and this receptor regulates bone resorption (30). In spite of the physiological significance of the Vn receptor in bone resorption, the ligand in the mineralized bone matrix has not been identified.
Although osteopontin has been co-localized in immunoelectron microscopic studies with the Vn receptor in areas of osteoclast adhesion (31), little attention has been paid to the classical ligand of the Vn receptor, Vn. The results of this study raise the possibility that Vn is an alternative ligand for avP3 in the bone matrix.
